Dr. Chung is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1514 Jefferson Hwy
New Orleans, LA 70121Phone+1 504-842-3330Fax+1 504-842-3884
Summary
- I am a board certified pathologist (AP/CP, hematopathology, molecular genetic pathology). I graduated from ACGME-accredited 2-year hematopathology and 1-year molecular genetic pathology fellowships.
Education & Training
- Methodist Hospital (Houston)Fellowship, Molecular Genetic Pathology, 2018 - 2019
- Methodist Hospital (Houston)Fellowship, Hematopathology, 2016 - 2018
- Rutgers Health/Robert Wood Johnson Medical SchoolChief Residency, Pathology-Anatomic and Clinical, 2014 - 2016
- University of Illinois College of Medicine at ChicagoResidency, Pathology-Anatomic and Clinical, 2012 - 2014
- Columbia UniversityMPH, General Public Health, 2011 - 2013
- Rowan University School of Osteopathic MedicineClass of 2011
- Boston University School of MedicineMA, Pharmacology & Experimental Therapeutics, 2000 - 2003
- University of ChicagoBA, Biological Sciences, 1991 - 1997
Certifications & Licensure
- LA State License 2019 - 2025
- MS State License 2019 - 2025
- PA State License 2016 - 2020
- NJ State License 2014 - 2018
- IL State License 2012 - 2015
- American Board of Pathology Pathology - Anatomic/Pathology - Clinical
- American Board of Pathology Molecular Genetic Pathology
- American Board of Pathology Pathology - Molecular Genetic
- American Board of Pathology Hematopathology
Awards, Honors, & Recognition
- Hematopathology Academic Excellence Award Houston Methodist Hospital, 2018
- Chief Hematopathology Fellow Houston Methodist Hospital, 2017-2018
- USCAP Stowell-Orbison Best Poster Competition United States and Canadian Academy of Pathology, 2013-2014, 2017-2018
- Join now to see all
Publications & Presentations
PubMed
- 34 citationsClinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant.Premal Lulla, Swati Naik, Spyridoula Vasileiou, Ifigeneia Tzannou, Ayumi Watanabe
Blood. 2021-05-13 - 7 citationsSeminal vesicle invasion combined with extraprostatic extension is associated with higher frequency of biochemical recurrence and lymph node metastasis than seminal ve...Aseeb Rehman, Ziad M. El-Zaatari, Sang H. Han, Steven S. Shen, Alberto G. Ayala
Annals of Diagnostic Pathology. 2020-08-24 - 22 citationsThe safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma.Premal Lulla, Ifigeneia Tzannou, Spyridoula Vasileiou, George Carrum, Carlos A. Ramos
Science Translational Medicine. 2020-07-29
Other
- Primary CNS lymphoma arising from the 4th ventricle: A case report and review of the literature.A Brozovich, D Ewing, E Burns, C Hatcher, G Acosta, U Khan, B Chung, L Samuel, J Randhawa, SR Pingali.
4/10/2019 - Tumor Associated Antigen Expression Profiles and Clinical Significance in Relapsed Multiple Myeloma Patients.BM Chung, Y Ren, S Mukhi, AM Leen, P Lulla.
United States and Canadian Association of Pathology (USCAP) - 3/18/2019 - Combined extraprostatic extension(EPE) and seminal vesicle invasion (SVI) of prostate cancers associated with worse biochemical failure (BCF) than SVI alone: proposal ...A Rehman, BM Chung, M Ketcham, S Han, B Miles, M Divatia, S Shen, AG Ayala, JY Ro.
United States and Canadian Association of Pathology (USCAP) - 3/2019 - Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: